Stocks · News reference
Alvotech And LOTTE Biologics Announce Long-Term Strategic Manufacturing Partnership For Biosimilar Products
Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New YorkStrategic long-term partnership to increase Alvotech’s global manufacturing capacity and support
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Alvotech Gets FDA Nod For Added US Manufacturing Capacity For Humira Biosimilar SIMLANDI, Doubling Drug Substance Capacity At Reykjavik Site
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suitesFurther confirms resolution of FDA inspection-related matters at the
Alvotech shares are trading higher after Barclays upgraded the stock from Underweight to Overweight rating and raised its price target from $4 to $8.